SOPHiA GENETICS SA
Close on Oct 19, 2026
- Market cap
- $479.21M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 4, 2026 | Before market open | $23.31M | $-0.30 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 3, 2026 | Before market open | $21.70M | $-0.28 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 5, 2025 | Before market open | $18.32M | $-0.33 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 4, 2025 | Before market open | $17.70M | $-0.23 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 6, 2024 | Before market open | $15.81M | $-0.23 | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 5, 2024 | Before market open | $17.00M | $-0.37 | – |
| Q2 FY2023 Ended Jun 30, 2023 | Aug 8, 2023 | Before market open | $15.05M | $-0.33 | – |
| Q4 FY2022 Ended Dec 31, 2022 | Mar 7, 2023 | Before market open | – | – | – |
| Q2 FY2022 Ended Jun 30, 2022 | Aug 9, 2022 | Before market open | – | – | – |
| Q4 FY2021 Ended Dec 31, 2021 | Mar 15, 2022 | Before market open | – | – | – |
Company guidance
Outlook given with results on Mar 3, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| Adjusted EBITDA lossnon-GAAP | Full-year | $29.00M to $32.00M | New |
| Full-year revenueGAAP | Full-year | $92.00M to $94.00M | New |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements SOPHiA GENETICS filed with the SEC
Index to Condensed Consolidated Financial Statements
EX-99.1 to Form 6-K
SOPHiA GENETICS Reports Second Quarter 2026 Results
EX-99.3 to Form 6-K
SOPHiA GENETICS Announces Proposed Public Offering of Ordinary Shares
EX-99.2 to Form 6-K
SOPHiA GENETICS Announces Closing of $57.5 Million Public Offering of
EX-99.3 to Form 6-K
Articles of Association of SOPHiA GENETICS SA Statuts de SOPHiA GENETICS SA
EX-99.1 to Form 6-K
EX-99.2 to Form 6-K
EX-99.2 to Form 6-K
EX-99.1 to Form 6-K
EX-99.1 to Form 6-K
EX-99.1 to Form 6-K
EX-99.1 to Form 6-K
EX-99.1 to Form 6-K
EX-99.1 to Form 6-K
EX-99.2 to Form 6-K
EX-99.2 to Form 6-K
EX-99.3 to Form 6-K
EX-99.3 to Form 6-K
Index to Condensed Consolidated Financial Statements
EX-99.1 to Form 6-K
SOPHiA GENETICS Reports First Quarter 2026 Results
EX-99.3 to Form 6-K
SOPHiA GENETICS Reports Fourth Quarter and Full Year 2025 Results
EX-99.1 to Form 6-K
Index to Consolidated Financial Statements
EX-99.1 to Form 6-K
Index to Consolidated Financial Statements
EX-99.1 to Form 6-K
SOPHiA GENETICS Reports Second Quarter 2025 Results
EX-99.3 to Form 6-K
Articles of Association of SOPHiA GENETICS SA Statuts de SOPHiA GENETICS SA
EX-99.1 to Form 6-K
EX-99.1 to Form 6-K
EX-99.1 to Form 6-K
To the shareholders of SOPHiA GENETICS SA (Nasdaq SOPH) (the Company)
EX-99.1 to Form 6-K
EX-99.2 to Form 6-K
EX-99.2 to Form 6-K
EX-99.3 to Form 6-K
EX-99.3 to Form 6-K
Index to Consolidated Financial Statements
EX-99.1 to Form 6-K
SOPHiA GENETICS Reports First Quarter 2025 Results
EX-99.3 to Form 6-K
SOPHiA GENETICS Reports Fourth Quarter and Full Year 2024 Results
EX-99.1 to Form 6-K
Index to Consolidated Financial Statements
EX-99.1 to Form 6-K
SOPHiA GENETICS Reports Third Quarter 2024 Results
EX-99.3 to Form 6-K
Index to Consolidated Financial Statements
EX-99.1 to Form 6-K